Literature DB >> 20473893

Vitamin D receptor rs2228570 polymorphism and invasive ovarian carcinoma risk: pooled analysis in five studies within the Ovarian Cancer Association Consortium.

Galina Lurie1, Lynne R Wilkens, Pamela J Thompson, Michael E Carney, Rachel T Palmieri, Paul D P Pharoah, Honglin Song, Estrid Hogdall, Susanne Kruger Kjaer, Richard A DiCioccio, Valerie McGuire, Alice S Whittemore, Simon A Gayther, Aleksandra Gentry-Maharaj, Usha Menon, Susan J Ramus, Marc T Goodman.   

Abstract

The association of invasive ovarian carcinoma risk with the functional polymorphism rs2228570 (aka rs10735810; FokI polymorphism) in the vitamin D receptor (VDR) gene was examined in 1820 white non-Hispanic cases and 3479 controls in a pooled analysis of five population-based case-control studies within the Ovarian Cancer Association Consortium. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using unconditional logistic regression. Carriers of the rare T allele were at increased risk of ovarian carcinoma compared to women with the CC genotype in all studies combined; each copy of the T allele was associated with a modest 9% increased risk (OR = 1.09; 95% CI: 1.01-1.19; p = 0.04). No significant heterogeneity among studies was observed (p = 0.37) and, after excluding the dataset from the Hawaii study, the risk association for rs2228570 among replication studies was unchanged (OR = 1.09; 95% CI: 1.00-1.19; p = 0.06). A stronger association of rs2228570 with risk was observed among younger women (aged < 50 years versus 50 years or older) (p = 0.04). In all studies combined, the increased risk per copy of the T allele among younger women was 24% (OR = 1.24; 95% CI: 1.04-1.47; p = 0.02). This association remained statistically significant after excluding the Hawaii data (OR = 1.20; 95% CI: 1.01-1.43; p = 0.04). No heterogeneity of the association was observed by stage (p = 0.46), tumor histology (p = 0.98), or time between diagnosis and interview (p = 0.94). This pooled analysis provides further evidence that the VDR rs2228570 polymorphism might influence ovarian cancer susceptibility.
Copyright © 2010 UICC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20473893      PMCID: PMC2972411          DOI: 10.1002/ijc.25403

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  34 in total

Review 1.  Role of genetic polymorphisms in ovarian cancer susceptibility: development of an international ovarian cancer association consortium.

Authors:  Andrew Berchuck; Joellen M Schildkraut; C Leigh Pearce; Georgia Chenevix-Trench; Paul D Pharoah
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

2.  Sunlight, vitamin D, and ovarian cancer mortality rates in US women.

Authors:  E S Lefkowitz; C F Garland
Journal:  Int J Epidemiol       Date:  1994-12       Impact factor: 7.196

3.  A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japanese women.

Authors:  H Arai; K Miyamoto; Y Taketani; H Yamamoto; Y Iemori; K Morita; T Tonai; T Nishisho; S Mori; E Takeda
Journal:  J Bone Miner Res       Date:  1997-06       Impact factor: 6.741

4.  Polymorphisms of interleukin (IL)-1alpha, IL-1beta, IL-6, IL-10, and IL-18 and the risk of ovarian cancer.

Authors:  Abigail W Bushley; Robert Ferrell; Katharine McDuffie; Keith Y Terada; Michael E Carney; Pamela J Thompson; Lynne R Wilkens; Ko-Hui Tung; Roberta B Ness; Marc T Goodman
Journal:  Gynecol Oncol       Date:  2004-12       Impact factor: 5.482

Review 5.  Vitamin D, calcium and prevention of breast cancer: a review.

Authors:  M Lipkin; H L Newmark
Journal:  J Am Coll Nutr       Date:  1999-10       Impact factor: 3.169

6.  Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D3 through the down-regulation of telomerase.

Authors:  Feng Jiang; Junying Bao; Pengfei Li; Santo V Nicosia; Wenlong Bai
Journal:  J Biol Chem       Date:  2004-10-12       Impact factor: 5.157

7.  Inhibition of c-myc in breast and ovarian carcinoma cells by 1,25-dihydroxyvitamin D3, retinoic acid and dexamethasone.

Authors:  D E Saunders; C Christensen; N L Wappler; J F Schultz; W D Lawrence; V K Malviya; J M Malone; G Deppe
Journal:  Anticancer Drugs       Date:  1993-04       Impact factor: 2.248

8.  The vitamin D receptor gene start codon polymorphism: a functional analysis of FokI variants.

Authors:  C Gross; A V Krishnan; P J Malloy; T R Eccleshall; X Y Zhao; D Feldman
Journal:  J Bone Miner Res       Date:  1998-11       Impact factor: 6.741

9.  Chemoprevention of colorectal neoplasia by estrogen: potential role of vitamin D activity.

Authors:  Petr Protiva; Heide S Cross; Michael E Hopkins; Enikö Kállay; Giovanna Bises; Eleanor Dreyhaupt; Leonard Augenlicht; Martin Lipkin; Martin Lesser; Elayne Livote; Peter R Holt
Journal:  Cancer Prev Res (Phila)       Date:  2009-01

10.  Receptors for 1,25-dihydroxyvitamin D3 in gynecologic neoplasms.

Authors:  D E Saunders; C Christensen; W D Lawrence; V K Malviya; J M Malone; J R Williams; G Deppe
Journal:  Gynecol Oncol       Date:  1992-02       Impact factor: 5.482

View more
  19 in total

1.  Polymorphic variants in the vitamin D pathway genes and the risk of ovarian cancer among non-carriers of BRCA1/BRCA2 mutations.

Authors:  Adrianna Mostowska; Stefan Sajdak; Piotr Pawlik; Margarita Lianeri; Paweł P Jagodzinski
Journal:  Oncol Lett       Date:  2015-12-15       Impact factor: 2.967

2.  The VDR gene FokI polymorphism and ovarian cancer risk.

Authors:  Hui Xu; Su Li; Jian-Qing Qiu; Xiao-Lin Gao; Ping Zhang; Yong-Xia Yang
Journal:  Tumour Biol       Date:  2013-12

3.  Placental genetic variations in vitamin D metabolism and birthweight.

Authors:  Tsegaselassie Workalemahu; Sylvia E Badon; Michal Dishi-Galitzky; Chunfang Qiu; Michelle A Williams; Tanya Sorensen; Daniel A Enquobahrie
Journal:  Placenta       Date:  2016-12-27       Impact factor: 3.481

4.  Cataract and ovarian carcinoma: is the vitamin D hypothesis alive?

Authors:  Galina Lurie; Rayna K Matsuno; Lynne R Wilkens; Pamela J Thompson; Nicholas J Ollberding; Michael E Carney; Marc T Goodman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-10-05       Impact factor: 4.254

5.  Vitamin D receptor gene BsmI and FokI polymorphisms in relation to ovarian cancer risk in the Polish population.

Authors:  Adrianna Mostowska; Stefan Sajdak; Piotr Pawlik; Margarita Lianeri; Pawel P Jagodzinski
Journal:  Genet Test Mol Biomarkers       Date:  2013-01-15

6.  Dairy foods and nutrients in relation to risk of ovarian cancer and major histological subtypes.

Authors:  Melissa A Merritt; Daniel W Cramer; Allison F Vitonis; Linda J Titus; Kathryn L Terry
Journal:  Int J Cancer       Date:  2012-07-24       Impact factor: 7.396

7.  Investigation of the vitamin D receptor gene (VDR) and its interaction with protein tyrosine phosphatase, non-receptor type 2 gene (PTPN2) on risk of islet autoimmunity and type 1 diabetes: the Diabetes Autoimmunity Study in the Young (DAISY).

Authors:  B Frederiksen; E Liu; J Romanos; A K Steck; X Yin; M Kroehl; T E Fingerlin; H Erlich; G S Eisenbarth; M Rewers; J M Norris
Journal:  J Steroid Biochem Mol Biol       Date:  2012-09-07       Impact factor: 4.292

8.  Vitamin D receptor (VDR) polymorphisms and risk of ovarian cancer in Caucasian and African American women.

Authors:  Delores J Grant; Cathrine Hoyo; Lucy Akushevich; Edwin S Iversen; Regina Whitaker; Jeffrey Marks; Andrew Berchuck; Joellen M Schildkraut
Journal:  Gynecol Oncol       Date:  2012-12-21       Impact factor: 5.482

9.  Vitamin D receptor rs2228570 polymorphism and susceptibly to ovarian cancer: a meta-analysis.

Authors:  Su Li; Hui Xu; Shuang-Cheng Li; Xiang-Qun Qi; Wen-Juan Sun
Journal:  Tumour Biol       Date:  2013-10-18

10.  rs12512631 on the group specific complement (vitamin D-binding protein GC) implicated in melanoma susceptibility.

Authors:  Maria Peña-Chilet; Maider Ibarrola-Villava; Manuel Martin-González; Marta Feito; Cristina Gomez-Fernandez; Dolores Planelles; Gregorio Carretero; Ana Lluch; Eduardo Nagore; Gloria Ribas
Journal:  PLoS One       Date:  2013-03-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.